Immunic, Inc.

IMUX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$101-$94-$120-$93
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$4
Stock-Based Comp.$9$7$8$6
Change in WC$1$15$10-$9
Other Non-Cash$7$1$38$9
Operating Cash Flow-$85-$71-$65-$83
Investing Activities
PP&E Inv.-$0-$0-$0-$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0-$10$0
Inv. Sales/Matur.$0$10$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$0$9-$10-$0
Financing Activities
Debt Repay.$74$0$0$0
Stock Issued$0$1$40$43
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$56$0
Financing Cash Flow$75$1$96$43
Forex Effect-$1$0-$1-$0
Net Chg. in Cash-$11-$60$20-$41
Supplemental Information
Beg. Cash$47$107$87$127
End Cash$36$47$107$87
Free Cash Flow-$85-$71-$65-$83
Immunic, Inc. (IMUX) Financial Statements & Key Stats | AlphaPilot